Robenacoxib shows efficacy for the treatment of chronic degenerative joint disease-associated pain in cats: a randomized and blinded pilot clinical trial

Abstract The main objective of this pilot clinical trial was to evaluate outcome measures for the assessment of the nonsteroidal anti-inflammatory drug (NSAID) robenacoxib in cats with degenerative joint disease-associated pain (DJD-pain). Otherwise healthy cats (n = 109) with DJD-pain entered a par...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Derek Adrian, Jonathan N. King, Rudolph S. Parrish, Stephen B. King, Steven C. Budsberg, Margaret E. Gruen, B. Duncan X. Lascelles
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/fb60e1d331c4401f95a2359a9659a4cd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fb60e1d331c4401f95a2359a9659a4cd
record_format	dspace
spelling	oai:doaj.org-article:fb60e1d331c4401f95a2359a9659a4cd2021-12-02T14:26:51ZRobenacoxib shows efficacy for the treatment of chronic degenerative joint disease-associated pain in cats: a randomized and blinded pilot clinical trial10.1038/s41598-021-87023-22045-2322https://doaj.org/article/fb60e1d331c4401f95a2359a9659a4cd2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87023-2https://doaj.org/toc/2045-2322Abstract The main objective of this pilot clinical trial was to evaluate outcome measures for the assessment of the nonsteroidal anti-inflammatory drug (NSAID) robenacoxib in cats with degenerative joint disease-associated pain (DJD-pain). Otherwise healthy cats (n = 109) with DJD-pain entered a parallel group, randomized, blinded clinical trial. Cats received placebo (P) or robenacoxib (R) for two consecutive 3-week periods. Treatment groups were PP, RR, and RP. Actimetry and owner-assessment data were collected. Data were analyzed using mixed-effects and generalized mixed-effects linear models. Activity data showed high within-cat and between-cat variability, and 82.4% of the values were zero. Compared to placebo, mean total activity was higher (5.7%) in robenacoxib-treated cats (p = 0.24); for the 80th percentile of activity, more robenacoxib-treated cats had a > 10% increase in activity after 3 (p = 0.046) and 6 weeks (p = 0.026). Robenacoxib treatment significantly decreased owner-assessed disability, (p = 0.01; 49% reduction in disability; effect size ~ 0.3), and improved temperament (p = 0.0039) and happiness (p = 0.021) after 6 weeks. More robenacoxib-treated cats were successes at 6 weeks (p = 0.018; NNT: 3.8). Adverse effect frequencies were similar across groups. Results identified suitable endpoints for confirmatory studies, while also indicating efficacy of robenacoxib in cats with DJD-pain.Derek AdrianJonathan N. KingRudolph S. ParrishStephen B. KingSteven C. BudsbergMargaret E. GruenB. Duncan X. LascellesNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Derek Adrian Jonathan N. King Rudolph S. Parrish Stephen B. King Steven C. Budsberg Margaret E. Gruen B. Duncan X. Lascelles Robenacoxib shows efficacy for the treatment of chronic degenerative joint disease-associated pain in cats: a randomized and blinded pilot clinical trial
description	Abstract The main objective of this pilot clinical trial was to evaluate outcome measures for the assessment of the nonsteroidal anti-inflammatory drug (NSAID) robenacoxib in cats with degenerative joint disease-associated pain (DJD-pain). Otherwise healthy cats (n = 109) with DJD-pain entered a parallel group, randomized, blinded clinical trial. Cats received placebo (P) or robenacoxib (R) for two consecutive 3-week periods. Treatment groups were PP, RR, and RP. Actimetry and owner-assessment data were collected. Data were analyzed using mixed-effects and generalized mixed-effects linear models. Activity data showed high within-cat and between-cat variability, and 82.4% of the values were zero. Compared to placebo, mean total activity was higher (5.7%) in robenacoxib-treated cats (p = 0.24); for the 80th percentile of activity, more robenacoxib-treated cats had a > 10% increase in activity after 3 (p = 0.046) and 6 weeks (p = 0.026). Robenacoxib treatment significantly decreased owner-assessed disability, (p = 0.01; 49% reduction in disability; effect size ~ 0.3), and improved temperament (p = 0.0039) and happiness (p = 0.021) after 6 weeks. More robenacoxib-treated cats were successes at 6 weeks (p = 0.018; NNT: 3.8). Adverse effect frequencies were similar across groups. Results identified suitable endpoints for confirmatory studies, while also indicating efficacy of robenacoxib in cats with DJD-pain.
format	article
author	Derek Adrian Jonathan N. King Rudolph S. Parrish Stephen B. King Steven C. Budsberg Margaret E. Gruen B. Duncan X. Lascelles
author_facet	Derek Adrian Jonathan N. King Rudolph S. Parrish Stephen B. King Steven C. Budsberg Margaret E. Gruen B. Duncan X. Lascelles
author_sort	Derek Adrian
title	Robenacoxib shows efficacy for the treatment of chronic degenerative joint disease-associated pain in cats: a randomized and blinded pilot clinical trial
title_short	Robenacoxib shows efficacy for the treatment of chronic degenerative joint disease-associated pain in cats: a randomized and blinded pilot clinical trial
title_full	Robenacoxib shows efficacy for the treatment of chronic degenerative joint disease-associated pain in cats: a randomized and blinded pilot clinical trial
title_fullStr	Robenacoxib shows efficacy for the treatment of chronic degenerative joint disease-associated pain in cats: a randomized and blinded pilot clinical trial
title_full_unstemmed	Robenacoxib shows efficacy for the treatment of chronic degenerative joint disease-associated pain in cats: a randomized and blinded pilot clinical trial
title_sort	robenacoxib shows efficacy for the treatment of chronic degenerative joint disease-associated pain in cats: a randomized and blinded pilot clinical trial
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/fb60e1d331c4401f95a2359a9659a4cd
work_keys_str_mv	AT derekadrian robenacoxibshowsefficacyforthetreatmentofchronicdegenerativejointdiseaseassociatedpainincatsarandomizedandblindedpilotclinicaltrial AT jonathannking robenacoxibshowsefficacyforthetreatmentofchronicdegenerativejointdiseaseassociatedpainincatsarandomizedandblindedpilotclinicaltrial AT rudolphsparrish robenacoxibshowsefficacyforthetreatmentofchronicdegenerativejointdiseaseassociatedpainincatsarandomizedandblindedpilotclinicaltrial AT stephenbking robenacoxibshowsefficacyforthetreatmentofchronicdegenerativejointdiseaseassociatedpainincatsarandomizedandblindedpilotclinicaltrial AT stevencbudsberg robenacoxibshowsefficacyforthetreatmentofchronicdegenerativejointdiseaseassociatedpainincatsarandomizedandblindedpilotclinicaltrial AT margaretegruen robenacoxibshowsefficacyforthetreatmentofchronicdegenerativejointdiseaseassociatedpainincatsarandomizedandblindedpilotclinicaltrial AT bduncanxlascelles robenacoxibshowsefficacyforthetreatmentofchronicdegenerativejointdiseaseassociatedpainincatsarandomizedandblindedpilotclinicaltrial
_version_	1718391347939901440

Robenacoxib shows efficacy for the treatment of chronic degenerative joint disease-associated pain in cats: a randomized and blinded pilot clinical trial

Ejemplares similares